BR112015032161A2 - método para prevenir e/ou tratar encefalopatia traumática crônica, composição farmacêutica e uso de antagonista do receptor da substância p - Google Patents

método para prevenir e/ou tratar encefalopatia traumática crônica, composição farmacêutica e uso de antagonista do receptor da substância p

Info

Publication number
BR112015032161A2
BR112015032161A2 BR112015032161A BR112015032161A BR112015032161A2 BR 112015032161 A2 BR112015032161 A2 BR 112015032161A2 BR 112015032161 A BR112015032161 A BR 112015032161A BR 112015032161 A BR112015032161 A BR 112015032161A BR 112015032161 A2 BR112015032161 A2 BR 112015032161A2
Authority
BR
Brazil
Prior art keywords
preventing
treating chronic
pharmaceutical composition
receptor antagonist
chronic traumatic
Prior art date
Application number
BR112015032161A
Other languages
English (en)
Inventor
Vink Robert
Original Assignee
Eustralis Pharmaceuticals Ltd Trading As Pressura Neuro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013902455A external-priority patent/AU2013902455A0/en
Application filed by Eustralis Pharmaceuticals Ltd Trading As Pressura Neuro filed Critical Eustralis Pharmaceuticals Ltd Trading As Pressura Neuro
Publication of BR112015032161A2 publication Critical patent/BR112015032161A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

“método para prevenir e/ou tratar encefalopatia traumática crônica, composição farmacêutica e uso de antagonista do receptor da substância p” resumo a presente invenção refere-se a um método para prevenir e/ou tratar encefalopatia traumática crônica. 1/1
BR112015032161A 2013-07-02 2014-07-02 método para prevenir e/ou tratar encefalopatia traumática crônica, composição farmacêutica e uso de antagonista do receptor da substância p BR112015032161A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2013902455A AU2013902455A0 (en) 2013-07-02 Method for preventing and/or treating chronic traumatic encephalopathy - i
PCT/AU2014/050107 WO2015000032A1 (en) 2013-07-02 2014-07-02 Method for preventing and/or treating chronic traumatic encephalopathy-i

Publications (1)

Publication Number Publication Date
BR112015032161A2 true BR112015032161A2 (pt) 2017-07-25

Family

ID=52142941

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015032161A BR112015032161A2 (pt) 2013-07-02 2014-07-02 método para prevenir e/ou tratar encefalopatia traumática crônica, composição farmacêutica e uso de antagonista do receptor da substância p

Country Status (15)

Country Link
US (3) US10729677B2 (pt)
EP (1) EP3016642B1 (pt)
JP (1) JP2016523866A (pt)
KR (1) KR20160030506A (pt)
CN (1) CN105451727B (pt)
AU (2) AU2014286925A1 (pt)
BR (1) BR112015032161A2 (pt)
CA (1) CA2914515C (pt)
HK (1) HK1220642A1 (pt)
IL (1) IL242899B (pt)
MX (1) MX370176B (pt)
RU (1) RU2016103099A (pt)
SG (1) SG11201509932XA (pt)
WO (1) WO2015000032A1 (pt)
ZA (1) ZA201508871B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014286925A1 (en) 2013-07-02 2015-12-17 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Method for preventing and/or treating chronic traumatic encephalopathy-I
RU2709614C1 (ru) * 2018-03-06 2019-12-19 Арман Женисович ЛУРЬЕ Способ лечения энцефалопатии
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ514600A0 (en) * 2000-01-18 2000-02-10 James Cook University Brain injury treatment
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
WO2008067610A1 (en) 2006-12-08 2008-06-12 Adelaide Research & Innovation Pty Ltd Method for reducing inflammatory responses and inflammation
AU2008278273A1 (en) 2007-07-19 2009-01-22 Adelaide Research & Innovation Pty Ltd Method for reducing intracranial pressure
AU2010296044B2 (en) * 2009-09-18 2015-05-14 Chase Pharmaceuticals Corporation Method and composition for treating Alzheimer-type dementia
US8992951B2 (en) * 2013-01-09 2015-03-31 Sapna Life Sciences Corporation Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma
CA2831054C (en) * 2013-01-09 2016-08-30 Sapna Life Sciences Corp. Formulations, and methods for their use in treatment of neuropathology and neurodegeneration as a result of traumatic injury
US20140322252A1 (en) 2013-04-26 2014-10-30 Michael Ruff Peptides for Treating Alzheimers's Disease and Related Conditions
AU2014286925A1 (en) 2013-07-02 2015-12-17 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Method for preventing and/or treating chronic traumatic encephalopathy-I
KR102275705B1 (ko) 2014-07-11 2021-07-09 삼성전자주식회사 웨이퍼 대 웨이퍼 접합 구조

Also Published As

Publication number Publication date
AU2014286925A1 (en) 2015-12-17
CN105451727A (zh) 2016-03-30
IL242899B (en) 2018-12-31
US20210100773A1 (en) 2021-04-08
US20220218663A1 (en) 2022-07-14
CA2914515A1 (en) 2015-01-08
EP3016642A1 (en) 2016-05-11
ZA201508871B (en) 2017-04-26
MX370176B (es) 2019-12-04
AU2019257493B2 (en) 2021-04-01
JP2016523866A (ja) 2016-08-12
HK1220642A1 (zh) 2017-05-12
RU2016103099A (ru) 2017-08-07
MX2015017880A (es) 2016-09-22
EP3016642B1 (en) 2019-03-13
SG11201509932XA (en) 2016-01-28
US11426384B2 (en) 2022-08-30
EP3016642A4 (en) 2017-03-08
AU2019257493A1 (en) 2019-11-21
KR20160030506A (ko) 2016-03-18
RU2016103099A3 (pt) 2018-05-25
CN105451727B (zh) 2019-04-23
US20160143881A1 (en) 2016-05-26
US10729677B2 (en) 2020-08-04
CA2914515C (en) 2018-12-11
WO2015000032A1 (en) 2015-01-08

Similar Documents

Publication Publication Date Title
CL2015003314A1 (es) Inhibidores de acc y usos de los mismos
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
BR112015029969A2 (pt) tratamento de câncer usando moduladores de isoformas quinase pi3
CL2014000543A1 (es) Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer.
BR112015031903A8 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
CL2015003315A1 (es) Inhibidores de acc y usos de los mismos
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
BR112016000489A2 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
CU20130115A7 (es) Compuestos y composiciones como inhibidores de trk
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
BR112015006019A2 (pt) composto selecionado, composição farmacêutica, método para tratar uma doença ou distúrbio, uso de um composto, kit para tratar uma condição mediada por pim quinase e invenção.
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
BR112015022566A2 (pt) composto e composição farmacêutica
BR112017007123A2 (pt) derivados de tetrahidroisoquinolina
ECSP16078782A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
BR112014032510A2 (pt) composto, composição farmacêutica, método para tratar ou prevenir uma doença ou desordem, e, uso de um composto.
BR112015030385A8 (pt) composto, composto para uso e composição farmacêutica
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
CR20160460A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
BR112015000649A2 (pt) compostos, composição farmacêutica, uso de um composto, método para tratar ou melhorar câncer e invenção
CL2016000325A1 (es) Antagonistas de vía para tratar trastornos del sueño por cambio de fase
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
BR112017002852A2 (pt) compostos de azetidiniloxifenilpirrolidina
BR112014016736A2 (pt) composto, composição farmacêutica, método para tratamento, uso de um composto e invenção

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]